Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: A retrospective evaluation of safety and efficacy

Ajay K. Gopal, Nancy L. Bartlett, Andres Forero-Torres, Anas Younes, Robert Chen, Jonathan W. Friedberg, Jeffrey V. Matous, Andrei R. Shustov, Scott E. Smith, Jasmine Zain, Megan M. O'Meara, Michelle A. Fanale

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

Older adults constitute a significant proportion of the cancer population, but are underrepresented in clinical trials. We conducted a retrospective analysis of the safety and efficacy of brentuximab vedotin in adults ≥ 60 years with relapsed CD30-positive lymphomas. Baseline characteristics and safety data were compared for older (median age 66) and younger patients (< 60 years, median age 32). Exposure to brentuximab vedotin was comparable. Older patients had more preexisting conditions (median 11 vs. 6) and were receiving more concomitant medications (median 7.5 vs. 4). Higher rates of anemia (30% vs. 10%), peripheral sensory neuropathy (60% vs. 46%), fatigue (58% vs. 43%) and adverse events ≥ grade 3 (70% vs. 56%) occurred in older patients. Objective response rates were 56% and 100% in older patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma, respectively. With appropriate monitoring, brentuximab vedotin may represent a meaningful clinical option for older patients with relapsed CD30-positive lymphomas.

Original languageEnglish
Pages (from-to)2328-2334
Number of pages7
JournalLeukemia and Lymphoma
Volume55
Issue number10
DOIs
StatePublished - Oct 1 2014

Keywords

  • Elderly
  • Hodgkin lymphoma
  • Lymphomas
  • T-cell lymphoma

Fingerprint

Dive into the research topics of 'Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: A retrospective evaluation of safety and efficacy'. Together they form a unique fingerprint.

Cite this